[
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA) Faces Criticism from Cramer Amid High R&D Spending and Revenue Struggles",
    "summary": "We recently published a list of 14 Stocks That Jim Cramer Recently Talked About. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer recently talked about. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer continued to talk about […]",
    "url": "https://finnhub.io/api/news?id=b3c86eb93661de4e70074123efc4f2be20f77b45a8d5f12d1bed8214fa5c8ae7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734634478,
      "headline": "Moderna, Inc. (MRNA) Faces Criticism from Cramer Amid High R&D Spending and Revenue Struggles",
      "id": 132062427,
      "image": "https://s.yimg.com/ny/api/res/1.2/ss7LBw0NkRteO60GW_xAKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3355ab936103e2e5a7e230b963727612",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We recently published a list of 14 Stocks That Jim Cramer Recently Talked About. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer recently talked about. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer continued to talk about […]",
      "url": "https://finnhub.io/api/news?id=b3c86eb93661de4e70074123efc4f2be20f77b45a8d5f12d1bed8214fa5c8ae7"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
    "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
    "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734595200,
      "headline": "Merck’s RSV antibody could soon paddle into the rough waters of a crowded market",
      "id": 132052818,
      "image": "https://imgproxy.divecdn.com/LWPxHVUcDkZMiMUsy0TWcd-p9KYWrzM3Siin1LumbOc/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjEwOTMxMjkxXzEuanBn.webp",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.",
      "url": "https://finnhub.io/api/news?id=a613b84ce88b1b8e0dc13b6f79749c525cdb020c8b612d9ab747fa678e682bd5"
    }
  }
]